UK regulatory approvals are now in place for the trials of the Novartis compound, AFQ056, for individuals with Fragile X syndrome. The Patrick Wild Centre is hosting these trials in the UK and will begin recruitment for both the adolescent and the adult trials in September 2011.

More information can be found on our Clinical Trials page.